Previous close | 206.06 |
Open | 208.81 |
Bid | 203.29 x 800 |
Ask | 214.32 x 800 |
Day's range | 206.58 - 209.62 |
52-week range | 180.93 - 348.67 |
Volume | |
Avg. volume | 358,580 |
Market cap | 8.083B |
Beta (5Y monthly) | 0.53 |
PE ratio (TTM) | 90.28 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.
Penumbra Inc (NYSE:PEN), a global healthcare company focused on innovative therapies, has seen a recent insider transaction according to the latest SEC filings.